$65.17
1.90% yesterday
Nasdaq, Sep 18, 10:00 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$65.17
+1.91 3.02% 1M
+7.83 13.66% 6M
+2.38 3.79% YTD
+5.66 9.51% 1Y
-10.74 14.15% 3Y
-13.37 17.02% 5Y
+16.29 33.33% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
-1.26 1.90%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Market capitalization $12.55b
Enterprise Value $11.07b
P/E (TTM) P/E ratio 183.63
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.87
P/S ratio (TTM) P/S ratio 3.25
P/B ratio (TTM) P/B ratio 4.17
Revenue growth (TTM) Revenue growth 9.78%
Revenue (TTM) Revenue $3.86b
EBIT (operating result TTM) EBIT $33.74m
Free Cash Flow (TTM) Free Cash Flow $-138.12m
Cash position $1.52b
EPS (TTM) EPS $0.35
P/E forward 80.93
P/S forward 3.09
EV/Sales forward 2.73
Short interest 9.98%
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Incyte forecast:

13x Buy
52%
11x Hold
44%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Incyte forecast:

Buy
52%
Hold
44%
Sell
4%

Financial data from Incyte

Assets
Dec '23
4,645 4,645
Cash 3,656 3,656
Claims 744 744
Inventories 63 63
Other current assets Other current assets Current assets 183 183
2,177 2,177
Property, plant and equipment 777 777
Financial assets 190 190
Intangible Assets 279 279
Other fixed assets Other assets Fixed assets 931 931
Total Assets 6,822 6,822
Liabilities
Dec '23
Equity 5,190 5,190
1,632 1,632
Current liabilities 1,240 1,240
Non-current liabilities 392 392
Total Capital 6,822 6,822

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
PRNewsWire
about 4 hours ago
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – Niktimvo approved by U.S. FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least ...
Neutral
Business Wire
4 days ago
DOHA, Qatar--(BUSINESS WIRE)--Doğuş Technology, one of Turkey's leading tech companies, will showcase its innovative, technology-driven solutions for the construction industry at ConteQ Expo 2024, alongside Doğuş Construction, at the Qatar National Convention Center from September 16-18. Both companies will present their projects that drive sector transformation by enhancing efficiency and sust...
Neutral
Business Wire
4 days ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,524
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today